Loading
Optheras is building ATLAS, a laser system meant to treat small, superficial bladder tumours in the outpatient clinic rather than the operating theatre. A first study is checking its distance sensor inside the bladder.
Optheras A/S, of Birkerod, Denmark, was founded by specialists from a large urology department and laser industry professionals, according to the company. It is developing ATLAS (Automatic Targeting Laser Ablation System), a platform for laser treatment of superficial bladder cancer outside the operating room with real-time assistive capabilities; the company says it is in development and not approved for commercial use. A feasibility investigation (NCT07860398) at Herlev, Denmark, tests a version of ATLAS without a treatment laser, assessing its distance sensor and guide beam on bladder tumour and normal bladder tissue in 25 people with Ta low-grade tumours during scheduled outpatient laser treatment. The company reports selection for MedTech Innovator's 2026 Execution Award finalists, the AUA Innovation Nexus Boot Camp 2026 and the FDA TPLC Advisory Program pilot. Its first registered study, NCT07860398, was posted on ClinicalTrials.gov in October 2026.
Shares Cystoscopy, blue-light imaging & TURBT, Non-muscle-invasive bladder cancer.
Shares Cystoscopy, blue-light imaging & TURBT, Non-muscle-invasive bladder cancer.
Shares Non-muscle-invasive bladder cancer, Thermal ablation (RFA, microwave, cryo).
Shares Cystoscopy, blue-light imaging & TURBT, Non-muscle-invasive bladder cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/